Citations

Clear

2286 citation(s) found for "Yu, Anthony".

A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing, advanced solid tumors.
Hann, Christine L. , Farago, Anna F. , Beltran, Himisha , Hendifar, Andrew , Anthony, Lowell , Lewis, Karl D. , Niu, Jiaxin , Chung, Christine H. , Cleary, James M. , Rossi, M. , Ludwig, Carrianne, Valenzuela, Ricardo Santoyo, Luo, Yan , Aggarwal, Rahul , Mansfield, Aaron S. , Hong, David S. , Waqar, Saiama N , Taylor, Matthew H. , Bryce, Alan H. , Tagawa, Scott T. , Valenzuela, Ricardo

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 3552-3552

10.1200/jco.2020.38.15_suppl.3552 Get It

3552 Background: Delta-like 3 (DLL3) is highly and specifically expressed in solid tumors, such as neuroendocrine carcinomas (NECs), malignant melanoma (MM), and medullary thyroid carcinoma (MTC). Rovalpituzumab tesirine (Rova-T) is a DLL3-targeting antibody-drug conjugate. Methods: This Phase 1/2 study (NCT02709889) enrolled patients with relapsed/refractory DLL3+ (>1% by IHC) advanced solid tumors and ECOG performance status of 0-1. Rova-T was given IV at 0.2, 0.3, or 0.4 mg/kg on d 1 of each 6-wk cycle (q6wk) for dose escalation (3+3 design) in disease-specific cohorts in Phase I. The recommended Phase 2 dose (RP2D) was tested in Phase II. Safety and dose-limiting toxicities (DLTs) were primary endpoints; efficacy outcomes were secondary endpoints. Results: The study enrolled 200 patients; 101 had NECs (large cell NEC [n=13], neuroendocrine prostate cancer [n=21], high-grade gastroenteropancreatic NEC [n=36], other [n=31]) and 99 had other solid tumors (MM [n=20], MTC [n=13], glioblastoma [GBM; n=23], other [n=43]). The median age was 61 y (range, 28-84); 63% were male. The RP2D was 0.3 mg/kg q6wk for 2 cycles in all cohorts. There were 7 DLTs in 5 patients: 2 with 0.2 mg/kg (Grade [Gr] 3 photosensitivity reaction, Gr 3 dyspnea), 2 with 0.3 mg/kg (1 with Gr 2 effusion, Gr 3 tumor lysis syndrome, and Gr 3 rhabdomyolysis; 1 with Gr 4 kidney injury), and 1 with 0.4 mg/kg (Gr 4 thrombocytopenia). Despite only 1 DLT identified with 0.4 mg/kg, the totality of the safety data suggested that this dose is not well tolerated. Common adverse events (AEs) in patients given 0.3 mg/kg (n=145) are shown (Table). Serious AEs occurred in 77/145 patients (53%), most commonly (≥3%) malignant neoplasm progression (n=18; 12%), pleural effusion (n=7; 5%), pericardial effusion (n=6; 4%), and dyspnea (n=5; 3%). The objective response rate (ORR) was 11% (21/200): 14 had NEC, 2 had MM, 2 had MTC, 2 had small cell carcinoma (SCC) not of lung origin (all partial responses), and 1 had GBM (complete response). In patients with NECs given 0.3 mg/kg, ORR, clinical benefit rate, and progression-free survival trended in favor of those with high DLL3-expressing tumors (≥50% by IHC) which represented 51% of NECs. Conclusions: Rova-T was tolerable in patients with advanced solid tumors at 0.3 mg/kg q6wk for 2 cycles. Antitumor activity was observed in patients with NEC, MM, MTC, SCC, and GBM. Clinical trial information: NCT02709889 . [Table: see text]
Leptomeningeal disease after surgical resection and radiosurgery for brain metastases and neurologic death: A multi-institutional analysis.
Asher, Anthony L. , Marcrom, Samuel , Fiveash, John B. , Foreman, Paul M. , Buchwald, Zachary S. , Curran, Walter J. , Patel, Kirtesh R., Breen, William G. , Brown, Paul D. , Grills, Inga S., Arden, Jessica D. , Foster, Lauren, Manning, Matthew A., Vaslow, Zachary , Burri, Stuart H., Soltys, Scott G. , Prabhu, Roshan S. , Turner, Brandon E. , Press, Robert H. , Jethwa, Krishan R.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 2524-2524

10.1200/jco.2020.38.15_suppl.2524 Get It

2524 Background: Postoperative radiosurgery (SRS) has been associated with up to 30% risk of subsequent leptomeningeal disease (LMD). We previously demonstrated that radiographic pattern of LMD (classical “sugarcoating” [cLMD] vs. nodular [nLMD]) in this setting is prognostic. The association between radiographic pattern of LMD, type of salvage treatment (tx), and neurologic death (ND) has not been well described. Methods: The records of patients (pts) with brain metastases (BM), of which 1 was resected and treated with adjunctive SRS, and who subsequently developed LMD were combined from 7 tertiary care centers. Pts with classically radiosensitive tumors or prior or planned whole brain radiotherapy (WBRT) were excluded. ND was defined as symptomatic CNS progression around the time of death without life threatening systemic symptoms or progression. Salvage radiotherapy (RT) for LMD was categorized according to use of WBRT vs. focal cranial RT. Results: The study cohort consisted of 147 pts, of which 125 had died with known cause, 107 also received LMD salvage tx, and 82 also had cranial MRI follow-up. The ND rate in the 125 pts who died with known cause was 79%; the rate in pts who underwent LMD salvage tx (n = 107) was 76%. Univariate logistic regression demonstrated radiographic pattern of LMD (cLMD vs. nLMD, odds ratio [OR] 2.9, p = 0.04) and 2nd LMD failure after salvage tx (OR 3.9, p = 0.02) as significantly associated with ND. The ND rate was 86% for cLMD vs. 68% for nLMD pattern. WBRT was used in 95% of pts with cLMD vs. 52% of pts with nLMD. In the nLMD cohort (n = 58), there was no difference in ND rate based on type of salvage RT (WBRT: 67% vs. focal cranial RT: 68%, p = 0.92). Second LMD failure (vs. not) was associated with higher ND in the nLMD cohort (77% vs. 52%, p = 0.02). Of the 26 pts with nLMD who experienced 2nd LMD failure, 7 had classical 2nd LMD, of which 100% experienced ND, and 19 had nodular 2nd LMD, of which 68% experienced ND (p = 0.09). Conclusions: LMD after surgery and SRS for brain metastases is a clinically significant event with high rates of neurologic death. Classical LMD pattern (vs. nodular) and 2nd LMD failure after salvage tx were significantly associated with higher risk of neurologic death. In the nodular LMD cohort, radiographic pattern of 2nd LMD may be associated with risk of subsequent neurologic death. Pts with nodular LMD treated with salvage focal cranial RT or WBRT had similar risk of neurologic death. Methods to decrease LMD and the subsequent high risk of neurologic death in this setting warrant investigation.
Randomized phase III trial of eribulin (E) versus standard weekly paclitaxel (P) as first- or second-line therapy for locally recurrent or metastatic breast cancer (MBC).
Liu, Minetta C. , Frith, Ashley , Lyss, Alan P., Weckstein, Douglas, Moreno‐Aspitia, Alvaro , Le‐Lindqwister, Nguyet, Wender, Donald B., Lewis, DeQuincy Andrew, Cole, John T., Jaslowski, Anthony J., Rowland, Kendrith M. , Openshaw, Thomas H. , Friday, Bret Edward Buckley, Asmus, Erik, Rogak, Lauren J. , Basch, Ethan , Hillman, David W. , Isaacs, Claudine , Fleming, Gini F. , Basch, Ethan , Dueck, Amylou C.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 1016-1016

10.1200/jco.2020.38.15_suppl.1016 Get It

1016 Background: The ph III EMBRACE trial of E vs physician’s choice of tx led to FDA approval of E as ≥3rd-line tx for MBC pts with prior exposure to anthracyclines/taxanes. The ph III BOLD 301 trial of E vs capecitabine in advanced BC treated with anthracyclines/taxanes showed a nonsignificant trend to improved median OS for all pts; pre-planned analysis by HER2 status revealed a nominally significant benefit for HER2- pts. Methods: RU011201I is an investigator initiated ph III trial with 1:1 randomization to E (1.4 mg/m2 D1,8 q21days) vs P (90 mg/m2 D1,8,15 q28days) within strata defined by (neo)adjuvant taxanes (yes/no), HR status (+/-), and line of tx (1st/2nd). Pts had measurable or non-measurable disease by RECIST v1.1; new or progressive mets; peripheral neuropathy (PN) gr<2; ≤1 prior chemotx regimens for advanced or MBC. Asymptomatic brain mets with stable MRIs for >3 mos were allowed. (Neo)adjuvant taxanes were allowed if >12 mos between tx completion and disease recurrence. Radiographic studies occur q12wks. Survival data are collected q12wks after the Off-Tx Visit. Pts reported side effects weekly; post-baseline symptomatic AE rates worse than baseline were compared between arms using Fisher’s exact tests. We report clinical outcomes and the primary objective related to PRO-CTCAE use. Results: 201 pts enrolled 3/2014 - 5/2018 with 33.8 mos median f/u; 3 are on tx as of 2/20/20 (1E, 2P). Pt characteristics were the same between E vs P: median age 62 yrs (range 27-85); 42% prior taxane; 78% ER+; 70% starting 1st line tx. Baseline lesion distribution was similar except for lung mets (37E, 53P). No difference was seen between E vs P in PFS (5.7 vs 5.9 mos; P=0.72), OS (18.1 vs 16.4 mos; P=0.75), TTF (5.3 vs 4.9 mos; P=0.82), DOR (10.8 vs 12.3 mos; P=0.84), or number of metastatic events (55 vs 54). 37E and 36P pts required ≥1 dose reduction. Hematologic toxicities ≥ gr 3 were higher with E (40 vs 22%). PN events were similar: 56 vs 58 total, 4 vs 7 motor, 52 vs 51 sensory. Median duration of PN and median time to 1st PN event were 74 vs 140 and 56 vs 41 days. Worsened numbness/tingling severity and other pt-reported AE rates were similar, but worsened numbness/tingling interference (63% vs 78%, P=0.04) and vomiting frequency (35% vs 57%, P=0.005) were lower with E. Conclusions: Clinical outcomes were equivalent with E vs P as 1st/2nd line tx for HER2- advanced BC. The nature and severity of PN were similar between arms, but time of onset, duration, and interference with daily living favor E. E may be a suitable treatment option in this setting. Clinical trial information: NCT02037529 .
Impact of Dominant Symptom on 12-Month Patient-Reported Outcomes for Patients Undergoing Lumbar Spine Surgery
Devin, Clinton J. , Asher, Anthony L. , Archer, Kristin R. , Khan, Inamullah , Kerezoudis, Panagiotis , Alvi, Mohammed Ali , Pennings, Jacquelyn S. , Karacay, Bernes, Shaffrey, Christopher I. , Bisson, Erica F. , Knightly, John J. , Mummaneni, Praveen V., Foley, Kevin T. , Bydon, Mohamad , Alvi, Mohammed Ali , Goyal, Anshit , Mummaneni, Praveen V.

Mayo Clinic

Neurosurgery | May 21, 2020 | Volume: 87 | Issue: 5 | Pages: 1037-1045

10.1093/neuros/nyaa240 | PMID 32521016 Get It

Abstract BACKGROUND The impact of symptom characteristics on outcomes of spine surgery remains elusive. OBJECTIVE To determine the impact of symptom location, severity, and duration on outcomes following lumbar spine surgery. METHODS We queried the Quality Outcomes Database (QOD) for patients undergoing elective lumbar spine surgery for lumbar degenerative spine disease. Multivariable regression was utilized to determine the impact of preoperative symptom characteristics (location, severity, and duration) on improvement in disability, quality of life, return to work, and patient satisfaction at 1 yr. Relative predictor importance was determined using an importance metric defined as Wald χ 2 penalized by degrees of freedom. RESULTS A total of 22 022 subjects were analyzed. On adjusted analysis, we found patients with predominant leg pain were more likely to be satisfied ( P < .0001), achieve minimum clinically important difference (MCID) in Oswestry Disability Index (ODI) ( P = .002), and return to work ( P = .03) at 1 yr following surgery without significant difference in Euro-QoL-5D (EQ-5D) ( P = .09) [ref = predominant back pain]. Patients with equal leg and back pain were more likely to be satisfied ( P < .0001), but showed no significant difference in achieving MCID ( P = .22) or return to work ( P = .07). Baseline numeric rating scale-leg pain and symptom duration were most important predictors of achieving MCID and change in EQ-5D. Predominant symptom was not found to be an important determinant of return to work. Worker's compensation was found to be most important determinant of satisfaction and return to work. CONCLUSION Predominant symptom location is a significant determinant of functional outcomes following spine surgery. However, pain severity and duration have higher predictive importance. Return to work is more dependent on sociodemographic features as compared to symptom characteristics.
Wide Complex Tachycardia Differentiation: A Reappraisal of the State‐of‐the‐Art
Kashou, Anthony H. , Deshmukh, Abhishek , Asirvatham, Samuel J. , May, Adam M. , Asirvatham, Samuel J , May, Adam M , Noseworthy, Peter A. , DeSimone, Christopher V.

Mayo Clinic

Journal of the American Heart Association | May 19, 2020 | Volume: 9 | Issue: 11 | Pages: No page available

10.1161/jaha.120.016598 | PMID 32427020 Get It

Abstract The primary goal of the initial ECG evaluation of every wide complex tachycardia is to determine whether the tachyarrhythmia has a ventricular or supraventricular origin. The answer to this question drives immediate patient care decisions, ensuing clinical workup, and long‐term management strategies. Thus, the importance of arriving at the correct diagnosis cannot be understated and has naturally spurred rigorous research, which has brought forth an ever‐expanding abundance of manually applied and automated methods to differentiate wide complex tachycardias. In this review, we provide an in‐depth analysis of traditional and more contemporary methods to differentiate ventricular tachycardia and supraventricular wide complex tachycardia. In doing so, we: (1) review hallmark wide complex tachycardia differentiation criteria, (2) examine the conceptual and structural design of standard wide complex tachycardia differentiation methods, (3) discuss practical limitations of manually applied ECG interpretation approaches, and (4) highlight recently formulated methods designed to differentiate ventricular tachycardia and supraventricular wide complex tachycardia automatically.
Cortical atrophy patterns of incident MCI subtypes in the Mayo Clinic Study of Aging
Lundt, Emily S. , Albertson, Sabrina M., Spychalla, Anthony J., Kremers, Walter K. , Vemuri, Prashanthi , Bondi, Mark W. , Petersen, Ronald C. , Vemuri, Prashanthi , Kremers, Walter K , Machulda, Mary M. , Schwarz, Christopher G. , Mielke, Michelle M. , Jack, Clifford R. , Knopman, David S. , Jones, David T. , Lundt, Emily S

Mayo Clinic

Alzheimer's & Dementia | May 17, 2020 | Volume: 16 | Issue: 7 | Pages: 1013-1022

10.1002/alz.12108 | PMID 32418367 Get It

AbstractIntroductionWe examined differences in cortical thickness in empirically derived mild cognitive impairment (MCI) subtypes in the Mayo Clinic Study of Aging.MethodsWe compared cortical thickness of four incident MCI subtypes (n = 192) to 1257 cognitive unimpaired individuals.ResultsThe subtle cognitive impairment cluster had atrophy in the entorhinal and parahippocampal cortex. The amnestic, dysnomic, and dysexecutive clusters also demonstrated entorhinal cortex atrophy as well as thinning in temporal, parietal, and frontal isocortex in somewhat different patterns.DiscussionWe found patterns of atrophy in each of the incident MCI clusters that corresponded to their patterns of cognitive impairment. The identification of MCI subtypes based on cognitive and structural features may allow for more efficient trial and study designs. Given individuals in the subtle cognitive impairment cluster have less structural changes and cognitive decline and may represent the earliest group, this could be a unique group to target with early interventions.
Coronavirus Disease 2019 and the Cerebrovascular‐Cardiovascular Systems: What Do We Know So Far?
Larson, Anthony S. , Kadirvel, Ramanathan , Kallmes, David F. , Hassan, Ameer E , Brinjikji, Waleed , Savastano, Luis , Larson, Anthony , Hassan, Ameer E

Mayo Clinic

Journal of the American Heart Association | May 12, 2020 | Volume: 9 | Issue: 13 | Pages: No page available

10.1161/jaha.120.016793 | PMID 32393136 Get It

Abstract The severe acute respiratory syndrome coronavirus 2 pandemic of 2019 to 2020 has resulted in multiple hospitalizations, deaths, and economic hardships worldwide. Although respiratory involvement in patients with coronavirus disease 2019 ( COVID ‐19) is well known, the potential cardiovascular and cerebrovascular manifestations are less understood. We performed a PubMed and Google Scholar search and reviewed relevant literature on COVID ‐19 and cardiovascular system involvement. Severe acute respiratory syndrome coronavirus 2 possesses high affinity for angiotensin‐converting enzyme 2 receptor, which is highly concentrated in the lungs and cardiovascular tissue, thereby provoking concern for cardiovascular involvement in COVID ‐19 cases. Preexisting cardiovascular and cerebrovascular disease has been shown in previous reports to be a risk factor for severe infection. On the basis of our review of published studies, COVID ‐19 patients may be more likely to experience acute cardiac injury, arrhythmia, coagulation defects, and acute stroke and are likely to have poorer outcomes as a result. As the COVID ‐19 pandemic continues, more data about potential cardiovascular and cerebrovascular manifestations of the disease are required.
Natural History of  Very Early Onset Inflammatory Bowel Disease in North America: A Retrospective Cohort Study
Kerur, Basavaraj , Benchimol, Eric I. , Fiedler, Karoline , Stahl, Marisa G. , Hyams, Jeffrey S. , Stephens, Michael C., Lu, Ying , Pfefferkorn, Marian, Alkhouri, Raza, Strople, Jennifer , Kelsen, Judith R. , Siebold, Leah, Goyal, Alka , Rosh, Joel R. , LeLeiko, Neal S. , Limbergen, Johan Van , Guerrerio, Anthony L. , Maltz, Ross , Karam, Lina , Crowley, Eileen , Heyman, Melvin B. , Benkov, Keith , Noe, Joshua D. , Mouton, Dedrick, Pappa, Helen, Galanko, Joseph A. , Muise, Aleixo M. , Stephens, Michael, Leleiko, Neal S , Griffiths, Anne Marie , Deneau, Mark , Snapper, Scott B. , Kappelman, Michael D.

Mayo Clinic

Inflammatory Bowel Diseases | May 9, 2020 | Volume: 27 | Issue: 3 | Pages: 295-302

10.1093/ibd/izaa080 | PMID 32386060 Get It

Abstract Background The incidence of very early onset inflammatory bowel disease (VEOIBD) is increasing, yet the phenotype and natural history of VEOIBD are not well described. Methods We performed a retrospective cohort study of patients diagnosed with VEOIBD (6 years of age and younger) between 2008 and 2013 at 25 North American centers. Eligible patients at each center were randomly selected for chart review. We abstracted data at diagnosis and at 1, 3, and 5 years after diagnosis. We compared the clinical features and outcomes with VEOIBD diagnosed younger than 3 years of age with children diagnosed with VEOIBD at age 3 to 6 years. Results The study population included 269 children (105 [39%] Crohn’s disease, 106 [39%] ulcerative colitis, and 58 [22%] IBD unclassified). The median age of diagnosis was 4.2 years (interquartile range 2.9–5.2). Most (94%) Crohn’s disease patients had inflammatory disease behavior (B1). Isolated colitis (L2) was the most common disease location (70% of children diagnosed younger than 3 years vs 43% of children diagnosed 3 years and older; P = 0.10). By the end of follow-up, stricturing/penetrating occurred in 7 (6.6%) children. The risk of any bowel surgery in Crohn’s disease was 3% by 1 year, 12% by 3 years, and 15% by 5 years and did not differ by age at diagnosis. Most ulcerative colitis patients had pancolitis (57% of children diagnosed younger than 3 years vs 45% of children diagnosed 3 years and older; P = 0.18). The risk of colectomy in ulcerative colitis/IBD unclassified was 0% by 1 year, 3% by 3 years, and 14% by 5 years and did not differ by age of diagnosis. Conclusions Very early onset inflammatory bowel disease has a distinct phenotype with predominantly colonic involvement and infrequent stricturing/penetrating disease. The cumulative risk of bowel surgery in children with VEOIBD was approximately 14%–15% by 5 years. These data can be used to provide anticipatory guidance in this emerging patient population.
Open versus minimally invasive decompression for low-grade spondylolisthesis: analysis from the Quality Outcomes Database
Bisson, Erica F. , Mummaneni, Praveen V. , Virk, Michael S. , Knightly, John J. , Alvi, Mohammed Ali , Chan, Andrew K. , Glassman, Steven D. , Foley, Kevin T. , Slotkin, Jonathan R., Potts, Eric A. , Shaffrey, Mark E., Shaffrey, Christopher I. , Haid, Regis W., Fu, Kai-Ming, Wang, Michael Y. , Park, Paul , Asher, Anthony L. , Bydon, Mohamad , Alvi, Mohammed Ali , Goyal, Anshit , Guan, Jian

Mayo Clinic

Journal of Neurosurgery: Spine | May 8, 2020 | Volume: 33 | Issue: 3 | Pages: 349-359

10.3171/2020.3.spine191239 | PMID 32384269 Get It

OBJECTIVELumbar decompression without arthrodesis remains a potential treatment option for cases of low-grade spondylolisthesis (i.e., Meyerding grade I). Minimally invasive surgery (MIS) techniques have recently been increasingly used because of their touted benefits including lower operating time, blood loss, and length of stay. Herein, the authors analyzed patients enrolled in a national surgical registry and compared the baseline characteristics and postoperative clinical and patient-reported outcomes (PROs) between patients undergoing open versus MIS lumbar decompression.METHODSThe authors queried the Quality Outcomes Database for patients with grade I lumbar degenerative spondylolisthesis undergoing a surgical intervention between July 2014 and June 2016. Among more than 200 participating sites, the 12 with the highest enrollment of patients into the lumbar spine module came together to initiate a focused project to assess the impact of fusion on PROs in patients undergoing surgery for grade I lumbar spondylolisthesis. For the current study, only patients in this cohort from the 12 highest-enrolling sites who underwent a decompression alone were evaluated and classified as open or MIS (tubular decompression). Outcomes of interest included PROs at 2 years; perioperative outcomes such as blood loss and complications; and postoperative outcomes such as length of stay, discharge disposition, and reoperations.RESULTSA total of 140 patients undergoing decompression were selected, of whom 71 (50.7%) underwent MIS and 69 (49.3%) underwent an open decompression. On univariate analysis, the authors observed no significant differences between the 2 groups in terms of PROs at 2-year follow-up, including back pain, leg pain, Oswestry Disability Index score, EQ-5D score, and patient satisfaction. On multivariable analysis, compared to MIS, open decompression was associated with higher satisfaction (OR 7.5, 95% CI 2.41–23.2, p = 0.0005). Patients undergoing MIS decompression had a significantly shorter length of stay compared to the open group (0.68 days [SD 1.18] vs 1.83 days [SD 1.618], p < 0.001).CONCLUSIONSIn this multiinstitutional prospective study, the authors found comparable PROs as well as clinical outcomes at 2 years between groups of patients undergoing open or MIS decompression for low-grade spondylolisthesis.
Adult diffuse glioma GWAS by molecular subtype identifies variants in D2HGDH and FAM20C
Eckel‐Passow, Jeanette E. , Drucker, Kristen , Kollmeyer, Thomas M. , Kosel, Matt, Decker, Paul A. , Molinaro, Annette M. , Rice, Terri, Praska, Corinne , Clark, Lauren E. , Caron, Alissa, Abyzov, Alexej , Batzler, Anthony , Song, Jun S. , Hansen, Helen M. , McCoy, Lucie , Bracci, Paige M. , Wiemels, Joseph L. , Wrensch, Margaret , Jenkins, Robert B. , Drucker, Kristen L, Kosel, Matt L, Praska, Corinne E, Clark, Lauren, Kollmeyer, Thomas , Abyzov, Alexej , Drucker, Kristen L , Kosel, Matthew , Decker, Paul A. , Molinaro, Annette M. , Pekmezci, Melike , Wiencke, John K. , Francis, Stephen , Burns, Terry C. , Giannini, Caterina , Lachance, Daniel Honore

Mayo Clinic

Neuro-Oncology | May 4, 2020 | Volume: 22 | Issue: 11 | Pages: 1602-1613

10.1093/neuonc/noaa117 | PMID 32386320 Get It

Abstract Background Twenty-five germline variants are associated with adult diffuse glioma, and some of these variants have been shown to be associated with particular subtypes of glioma. We hypothesized that additional germline variants could be identified if a genome-wide association study (GWAS) were performed by molecular subtype. Methods A total of 1320 glioma cases and 1889 controls were used in the discovery set and 799 glioma cases and 808 controls in the validation set. Glioma cases were classified into molecular subtypes based on combinations of isocitrate dehydrogenase (IDH) mutation, telomerase reverse transcriptase (TERT) promoter mutation, and 1p/19q codeletion. Logistic regression was applied to the discovery and validation sets to test for associations of variants with each of the subtypes. A meta-analysis was subsequently performed using a genome-wide P-value threshold of 5 × 10−8. Results Nine variants in or near D-2-hydroxyglutarate dehydrogenase (D2HGDH) on chromosome 2 were genome-wide significant in IDH-mutated glioma (most significant was rs5839764, meta P = 2.82 × 10−10). Further stratifying by 1p/19q codeletion status, one variant in D2HGDH was genome-wide significant in IDH-mutated non-codeleted glioma (rs1106639, meta P = 4.96 × 10−8). Further stratifying by TERT mutation, one variant near FAM20C (family with sequence similarity 20, member C) on chromosome 7 was genome-wide significant in gliomas that have IDH mutation, TERT mutation, and 1p/19q codeletion (rs111976262, meta P = 9.56 × 10−9). Thirty-six variants in or near GMEB2 on chromosome 20 near regulator of telomere elongation helicase 1 (RTEL1) were genome-wide significant in IDH wild-type glioma (most significant was rs4809313, meta P = 2.60 × 10−10). Conclusions Performing a GWAS by molecular subtype identified 2 new regions and a candidate independent region near RTEL1, which were associated with specific glioma molecular subtypes.